newsfilter
← Latest News
GlobeNewswire·

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

  • OKYO Pharma Chief Scientific Officer Raj Patil, PhD, purchased 3,363 ordinary shares at $1.49 per share on NASDAQ.
  • Patil's total holdings in OKYO Pharma now amount to 20,030 ordinary shares.
  • OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain & anterior segment eye diseases.
  • The company plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026.
  • The trial will enroll approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.